Showing results (81-90 of 93) with videos related to
Sort By:
Pageof 10
International Journal of Urology : Official Journal of the Japanese Urological Association|March 19, 2022
Clinical practice pattern in patients with advanced urothelial cancer who had progressed on pembrolizumab in the pre-enfortumab vedotin eraYuki Kita, Katsuhiro Ito, Tomoyasu Sano, et al.Nature Immunology|January 7, 2026
Active aldehydes accelerate CD8<sup>+</sup> T cell exhaustion by metabolic alteration in the tumor microenvironmentYasuharu Haku, Koji Kitaoka, Koki Ichimaru, et al.Cancer Science|December 7, 2020
Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumabTakashi Kobayashi, Katsuhiro Ito, Takahiro Kojima, et al.Cancer Immunology, Immunotherapy : CII|July 8, 2021
Pre-pembrolizumab neutrophil-to-lymphocyte ratio (NLR) predicts the efficacy of second-line pembrolizumab treatment in urothelial cancer regardless of the pre-chemo NLRTakashi Kobayashi, Katsuhiro Ito, Takahiro Kojima, et al.Cancer Medicine|May 1, 2021
Pembrolizumab for treating advanced urothelial carcinoma in patients with impaired performance status: Analysis of a Japanese nationwide cohortKatsuhiro Ito, Takashi Kobayashi, Takahiro Kojima, et al.Hinyokika Kiyo. Acta Urologica Japonica|January 7, 2020
[The Safety of Laparoscopic Radical Cystectomy during Initial Phases in a Japanese Multicenter Cohort]Toru Kanno, Takahiro Inoue, Katsuhiro Ito, et al.Urologic Oncology|August 29, 2021
Impact of prior intravesical bacillus Calmette-Guerin therapy on the effectiveness of pembrolizumab for patients with metastatic urothelial carcinomaRikiya Taoka, Takashi Kobayashi, Yu Hidaka, et al.Journal of Geriatric Oncology|July 9, 2021
Efficacy and safety of pembrolizumab for older patients with chemoresistant urothelial carcinoma assessed using propensity score matchingNaotaka Nishiyama, Takashi Kobayashi, Shintaro Narita, et al.International Journal of Urology : Official Journal of the Japanese Urological Association|September 21, 2021
Impact of the objective response to and number of cycles of platinum-based first-line chemotherapy for metastatic urothelial carcinoma on overall survival of patients treated with pembrolizumabMinoru Kato, Takashi Kobayashi, Yoshiyuki Matsui, et al.Clinical Genitourinary Cancer|July 31, 2025
Risk Stratification for the Prognosis of Patients With pT3aN0M0 Clear Cell Renal Cell CarcinomaShigeki Koterazawa, Takayuki Sumiyoshi, Katsuhiro Ito, et al.Pageof 10